Table 2 Safety profiles
From: Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials
| n = 21 | Percent | |
|---|---|---|
| Dose-limiting toxicity (DLT) | 0 | 0 |
| Severe adverse events (SAE) | 1 | 4.8 |
| Death (due to progressive disease) | 1 | 4.8 |
| Grade 3 or higher toxicity | 2 | 9.5 |
| Blood system disorders | 1 | 4.8 |
| Laboratory abnormalities | 1 | 4.8 |